In this article, Aptar Pharma uses inductively coupled plasma optical emission spectrometry (ICP-OES) to demonstrate that our proprietary manufacturing process optimizes the distribution of silicone oil on our PremiumCoat®. By limiting the quantity of silicone that comes in contact with the drug product, PremiumCoat® derisks the development of sensitive drugs.
Learn more about PremiumCoat® Platform
This Might Also Be of Interest

A pre-filled syringe platform for vaccines and large volume biologics
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

RFID-Enabled Rigid Needle Shields for unit serialization and tracking
Publications, Pharmaceutical, Device Innovations, Brand Differentiation, Market Insights, Product Solutions

Pre-filled syringes offer multiple benefits for COVID-19 vaccination
Publications, Pharmaceutical, Product Solutions, Innovation & Insights, Device Innovations, Market Insights

Advanced Stopper Solution – PremiumCoat®: Proven Compatibility With Current Vial S...
Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions